SCHEMBL6005316

SCHEMBL6005316

O=C(O)C(Oc1ccc(Cl)cc1)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PPARG P37231 17/20 0.59
PPARA Q07869 14/20 0.59
MEN1 O00255 1/20 0.57
POLB P06746 1/20 0.57
CASP3 P42574 1/20 0.57
KMT2A Q03164 1/20 0.57
SENP8 Q96LD8 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
SENP6 Q9GZR1 1/20 0.57
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21881525 1.00 PPARG (0.59) PPARGPPARAMEN1POLBCASP3
SCHEMBL11185611 0.95 PPARG (0.57) PPARGPPARAMEN1POLBCASP3
SCHEMBL11752505 0.93 PPARG (0.67) PPARGPPARAMEN1POLBCASP3
SCHEMBL14889080 0.93 PPARG (0.67) PPARGPPARAMEN1POLBCASP3
SCHEMBL934313 0.93 PPARG (0.61) PPARGPPARAMEN1POLBCASP3
SCHEMBL11378771 0.91 PPARG (0.55) PPARGPPARAMEN1POLBCASP3
SCHEMBL11565502 0.90 PPARG (0.60) PPARGPPARAMEN1POLBCASP3
SCHEMBL11563937 0.90 PPARG (0.60) PPARGPPARAMEN1POLBCASP3
SCHEMBL11566109 0.88 PPARG (0.57) PPARGPPARAMEN1POLBCASP3
SCHEMBL11574826 0.87 PPARG (0.57) PPARGPPARAMEN1POLBCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2520176-B1 Method for increasing the nutritional value of rapeseed and rape products with decreased oil content ROP REPCE OLAJ PELLET KFT (HU) 2019-02-20 EP disclosed
US-20120282369-A1 METHOD FOR INCREASING THE NUTRITIONAL VALUE OF RAPESEED AND RAPE PRODUCTS WITH DECREASED OIL CONTENT ROP REPCE-OLAJ-PELLET KFT. (HU) 2012-11-08 US disclosed
EP-2520176-A1 Method for increasing the nutritional value of rapeseed and rape products with decreased oil content ROP Repce-olaj-pellet Kft. (HU) 2012-11-07 EP disclosed
US-7105509-B2 Benzodiazepine derivatives as APP modulators MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-20040082572-A1 Benzodiazepine derivatives as app modulators MERCK SHARPE & DOHME LIMITED (GB) 2004-04-29 US disclosed
EP-1294702-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LTD. (GB) 2003-03-26 EP disclosed
WO-2001090084-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LIMITED (GB) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082572-A1 Benzodiazepine derivatives as app modulators BACE1, PSEN1, APP PPARG 255/4885PPARA 350/4885MEN1 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.